Drug intelligence / Profile preview

OD-01

Development stage
Unknown
Lead developer
OcuDyne
Modality
Peptides, Small Molecules
Administration
Ophthalmic
01

Overview

OD-01 is a proprietary, clear, aqueous, and preservative-free topical ophthalmic solution of cyclosporine developed by OcuDyne for the treatment of dry eye disease (DED). It is designed to improve upon existing cyclosporine formulations, such as emulsions, by providing a non-stinging and clear solution that enhances patient tolerability and ocular surface residence time. As a calcineurin inhibitor, the active ingredient cyclosporine binds to intracellular cyclophilin to form a complex that inhibits the phosphatase activity of calcineurin. This inhibition prevents the dephosphorylation and nuclear translocation of the nuclear factor of activated T-cells (NFAT), thereby suppressing T-cell activation and the subsequent release of pro-inflammatory cytokines like interleukin-2 (IL-2). By reducing ocular surface inflammation, OD-01 aims to restore normal tear production and alleviate the symptoms of DED.

Other names
cyclosporine ophthalmic solution
02

Targets

CN (Calcineurin)

Beyond the preview

Go deeper on OD-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on OD-01.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call